Navigation Links
Circulation Publishes Data Showing KYNAPID(TM) (Vernakalant Hydrochloride) Injection Rapidly Converted Short-Duration Atrial Fibrillation to Sinus Rhythm
Date:3/25/2008

tors including hypertension, obesity, diastolic dysfunction, inflammation, diabetes and sleep apnea.

About Astellas

Astellas Pharma US, Inc., located in Deerfield, Illinois, is a U.S. affiliate of Tokyo-based Astellas Pharma Inc. Astellas is a pharmaceutical company dedicated to improving the health of people around the world through the provision of innovative and reliable pharmaceutical products. The organization is committed to becoming a global category leader in focused areas by combining outstanding R&D and marketing capabilities. In the US, Astellas markets products in the areas of Immunology, Urology, Anti-Infectives, Cardiovascular and Dermatology. For more information about Astellas Pharma US, Inc., please visit our website at http://www.astellas.com/us.

About Cardiome

Cardiome Pharma Corp. is a product-focused cardiovascular drug development company with two late-stage clinical drug programs focused on atrial arrhythmia (intravenous and oral dosing), a Phase 1 program for GED-aPC, an engineered analog of recombinant human activated Protein C, and a pre-clinical program directed at improving cardiovascular function.

Vernakalant (iv) is the intravenous formulation of an investigational drug being evaluated for the acute conversion of atrial fibrillation. Positive top-line results from two pivotal Phase 3 trials for vernakalant (iv), called ACT 1 and ACT 3, were released in December 2004 and September 2005. Cardiome's co-development partner Astellas Pharma US, Inc. submitted a New Drug Application for vernakalant (iv) in December 2006. Positive top-line results from an additional Phase 3 study evaluating patients with post-operative atrial arrhythmia, called ACT 2, were released in June 2007. An open-label safety study evaluating recent-onset AF patients, called ACT 4, has completed.

Vernakalant (oral) is being investigated as a chronic-use oral drug for the main
'/>"/>

SOURCE Astellas Pharma US, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Thomson Scientific Publishes The Ones to Watch - A Quarterly Review of Phase Changes in the Pharmaceutical Pipeline
2. The Lancet Publishes Major Phase 3 Study on Novel Oral Direct Thrombin Inhibitor
3. The New England Journal of Medicine Publishes First Clinical Results for MedImmunes Chitinase-like Protein YKL-40 in Patients With Asthma
4. Biological Psychiatry Publishes Study Showing VYVANSE Demonstrated Significant Efficacy for Treatment of ADHD for up to 12 Hours After Administration
5. Franklin & Seidelmann Publishes Complex Podiatry MRI Study
6. Peregrine Reports Data Showing Bavituximabs Potential to Shrink Prostate Tumors
7. Peregrine Researchers Report Data Showing Bavituximabs Potential to Shrink Human Prostate Tumors in Model of Relapsed Disease
8. Kosan Presents Phase 1 Data Showing Antitumor Activity and Safety Profile of Epothilone KOS-1584 at AACR/NCI/EORTC Meeting
9. Human Genome Sciences Presents New Data Showing Anti-Tumor Activity And Safety Of Trail Receptor Antibodies In Combination With Chemotherapy
10. Studies Showing Significant Survival Improvement with Taxotere(R)-based Regimens in the Induction Treatment of Patients with Locally Advanced Head and Neck Cancer are Published in the Same Issue of the New England Journal of Medicine
11. IDM Pharma Announces Updated Phase 2 UVIDEM(R) Results Showing Durable Disease Control and Tolerability in Advanced Melanoma Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/17/2014)... NEW YORK , Sept. 17, 2014 ... on behalf of purchasers of the securities of PDL ... PDLI -News).  Such investors are advised to ... coordinator Eitan Kimelman at info@bgandg.com ... the Company and certain of its executives violated federal ...
(Date:9/17/2014)... EDEN PRAIRIE, Minn. , Sept. 17, 2014 /PRNewswire/ ... pioneer and global market leader of advanced imaging modalities ... Intravascular Ultrasound System in two live cases at the ... The cases were presented from Medstar Washington ... New York-Presbyterian Hospital/Columbia University Medical Center ( New ...
(Date:9/17/2014)... DALLAS , Sept. 17, 2014   OTEMR, ... 2014 Edition Complete EHR certification, which designates that the ... the Stage 1 and Stage 2 Meaningful Use measures ... and Reinvestment Act (ARRA).  ONETOUCH EMR 2.0 was certified ... an Office of the National Coordinator-Authorized Certification Body (ONC-ACB) ...
Breaking Medicine Technology:Shareholder Alert: Bronstein, Gewirtz & Grossman, LLC Investigates claims on behalf of Investors of PDL BioPharma, Inc. --PDLI 2ACIST Launches HDi High-Definition IVUS 2ACIST Launches HDi High-Definition IVUS 3OTEMR, Inc.'s ONETOUCH EMR Achieves ONC HIT 2014 Edition COMPLETE EHR Certification from ICSA Labs 2OTEMR, Inc.'s ONETOUCH EMR Achieves ONC HIT 2014 Edition COMPLETE EHR Certification from ICSA Labs 3
... speed and efficiency in the healthcare process remains ... essential variables to ensure healthy, accurate outcomes. Rising ... Align Networks, a physical medicine provider network, have ... pace of healthcare. (Logo:   http://photos.prnewswire.com/prnh/20080206/AQW030LOGO-b ...
... Cynosure, Inc. (Nasdaq: CYNO ), ... array of light-based aesthetic treatment systems, today announced ... financial results before the market opens on Tuesday, ... investors and analysts that day at 9:00 a.m. ...
Cached Medicine Technology:Realizing Healthcare Savings Using Real-Time Technology 2Realizing Healthcare Savings Using Real-Time Technology 3Cynosure to Host Third-Quarter 2010 Financial Results Conference Call on October 26 2
(Date:9/17/2014)... Catalent Pharma Solutions, the leading global ... for drugs, biologics and consumer health products, has ... and technology offer based on the company’s expertise ... 450,000 sq. ft. Kansas City, MO facility. , ... formulation, development, analytical expertise, scale up and manufacturing ...
(Date:9/17/2014)... JOLLA, CASeptember 17, 2014Scientists at The Scripps Research ... on vancomycin that is powerfully effective against vancomycin-resistant ... The new vancomycin analog appears to have not ... against which bacteria probably cannot evolve resistance quickly. ... once introduced will still be in clinical use ...
(Date:9/17/2014)... 17, 2014 Boston Children’s Museum ... a monthly concert series, introducing young Museum visitors ... Top, America’s premier national platform celebrating the stories, ... of the young musicians featured will also be ... Children’s Museum is fortunate to partner with the ...
(Date:9/17/2014)... A petition to ban the use of ... other gynecological surgeries has gathered nearly 85,000 signatures, Bernstein ... at least 84,908 supporters had signed the petition as ... report from ABC News, the Change.org petition was launched ... his wife, Dr. Amy Reed, was diagnosed with Stage ...
(Date:9/17/2014)... WEDNESDAY, Sept. 17, 2014 (HealthDay News) -- Present-day ... groups of ancient humans, according to a new ... descended from indigenous hunter-gatherers and early European farmers. ... samples revealed they are also the descendants of ... genetic material from this third ancestral group, researchers ...
Breaking Medicine News(10 mins):Health News:New OptiPact™ Technology Introduced by Catalent 2Health News:Scripps Research Institute chemists modify antibiotic to vanquish resistant bacteria 2Health News:Scripps Research Institute chemists modify antibiotic to vanquish resistant bacteria 3Health News:Boston Children's Museum Partners with From the Top to Offer Monthly Concert Series 2Health News:Boston Children's Museum Partners with From the Top to Offer Monthly Concert Series 3Health News:Power Morcellator Petition Nears 85,000 Signatures, Bernstein Liebhard LLP Reports 2Health News:Power Morcellator Petition Nears 85,000 Signatures, Bernstein Liebhard LLP Reports 3Health News:Power Morcellator Petition Nears 85,000 Signatures, Bernstein Liebhard LLP Reports 4Health News:Europeans Are Descendants of at Least 3 Ancient Human Groups: Study 2Health News:Europeans Are Descendants of at Least 3 Ancient Human Groups: Study 3
... Pancreatic cancer develops and spreads much more slowly than ... Hopkins investigators. The finding indicates that there is a ... disease. "For the first time, we have a ... when it would be best to intervene," according to ...
... tumors are one of the most lethal cancers, with fewer ... But a new study that peers deeply into the genetics ... opportunity for early diagnosis. In contrast to earlier predictions, many ... years to become lethal after the first genetic perturbations appear. ...
... PHILADELPHIA Demetrius H. Bagley, M.D., the Nathan Lewis Hatfield ... Medical College (JMC) of Thomas Jefferson University was recently honored ... Award in Endourology at the World Congress of Endourology. ... is fitting that Dr. Bagley was chosen to receive the ...
... News) --Mental health issues confronted by U.S. veterans returning ... by gender, new research suggests. Female veterans ... than are their male counterparts, according to a study ... the Veterans Administration from 2002 to 2008. They are ...
... efficient as humans mature. Now, for the first time ... Polytechnique Fdrale de Lausanne (EPFL) and the University of ... verified these gains with a powerful new computer program. ... the soon-to-be-released software allows for individualized maps of vital ...
... and University of North Carolina (UNC) researchers report in ... that narcotics and diagnostic testing are overused in ... overlook more effective treatments for neck pain, such as ... evidence to support the effectiveness of therapeutic exercise in ...
Cached Medicine News:Health News:Surprise finding: Pancreatic cancers progress to lethal stage slowly 2Health News:Surprise finding: Pancreatic cancers progress to lethal stage slowly 3Health News:Revising the timeline for deadly pancreatic cancer 2Health News:Revising the timeline for deadly pancreatic cancer 3Health News:Jefferson urologist awarded Lifetime Achievement Award from Endourological Society 2Health News:Mental Health Issues Differ for U.S. Male, Female Vets 2Health News:The brain's journey from early Internet to modern-day fiber optics -- all in 1 lifetime 2Health News:Narcotics and diagnostics overused in treatment of chronic neck pain 2
This 100 µL is the equivalent to the "Universal Blue" tips and fits virtually every manufacturer's 1000 µL Pipettor....
Conducting disposable tips provide cross-contaminationfree pipetting for sensitive applications such as PCR setup....
Volume range 0.2-10 l. Designed for pipetting micro-sized drops. Ideal for use with micro volume Finnpipettes....
Conducting disposable tips....
Medicine Products: